Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Relay Therapeutics Inc (NQ: RLAY ) 6.300 +0.040 (+0.64%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Relay Therapeutics Inc < Previous 1 2 3 4 5 6 Next > Largest Clinical-Stage BioTech Drug Stocks Declined 6% June 22, 2024 Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... Via Talk Markets AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th June 17, 2024 The global Via Talk Markets AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week June 10, 2024 The global Via Talk Markets Expert Ratings For Relay Therapeutics June 07, 2024 Via Benzinga Relay Therapeutics Discloses Three New Programs at New Program & Platform Event June 06, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Key Takeaways From Relay Therapeutics Analyst Ratings May 10, 2024 Via Benzinga Relay Therapeutics: Q4 Earnings Insights February 22, 2024 Via Benzinga Relay Therapeutics's Earnings: A Preview February 21, 2024 Via Benzinga Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 June 05, 2024 Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week May 27, 2024 This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... Via Talk Markets Relay Therapeutics to Participate in Upcoming Investor Conferences May 21, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 May 13, 2024 Company to disclose new programs from existing unnamed pre-clinical pipeline From Relay Therapeutics, Inc. Via GlobeNewswire 5 Of 7 AI Categories Rose, Slightly,Over Past Week May 11, 2024 The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence The 7 AI Categories Declined, On Average, The First Week Of May May 05, 2024 Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May May 05, 2024 We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. Via Talk Markets RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights May 02, 2024 Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 From Relay Therapeutics, Inc. Via GlobeNewswire Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 April 25, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week April 23, 2024 A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... Via Talk Markets Relay Therapeutics to Participate in Upcoming Investor Conferences April 11, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga AI Surge Ending: Only One Category Was Up This Week April 06, 2024 Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence 3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise March 15, 2024 Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities. Via InvestorPlace AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD March 04, 2024 Grand View Research says the global Via Talk Markets Relay Therapeutics to Participate in Three Upcoming Investor Conferences February 26, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights February 22, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For February 22, 2024 February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. Via Benzinga AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics February 19, 2024 The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024 February 15, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire The 7 Best Penny Stocks for 200% Returns February 06, 2024 Penny stocks often possess significant upside and these are no different with 200% returns expected by analysts. Via InvestorPlace < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.